Related references
Note: Only part of the references are listed.The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer
Hee Jin Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers
Giuseppe Di Caro et al.
CLINICAL CANCER RESEARCH (2014)
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Scott D. Brown et al.
GENOME RESEARCH (2014)
Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype
Mieke Van Bockstal et al.
VIRCHOWS ARCHIV (2014)
The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer
Z. M. A. Mohammed et al.
BRITISH JOURNAL OF CANCER (2013)
Tumour-infiltrating CD8+lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
A. N. Seo et al.
BRITISH JOURNAL OF CANCER (2013)
Increased lymphocytic infiltration in breast cancer correlated with molecular subtypes and HER2 gene amplification
Julia Y. S. Tsang et al.
HISTOPATHOLOGY (2013)
Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Hee Jin Lee et al.
JOURNAL OF BREAST CANCER (2013)
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin β-Producing Dendritic Cells in Human Breast Cancer
Ludovic Martinet et al.
JOURNAL OF IMMUNOLOGY (2013)
Characteristics of tertiary lymphoid structures in primary cancers
Jeremy Goc et al.
ONCOIMMUNOLOGY (2013)
Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
Sherene Loi
ONCOIMMUNOLOGY (2013)
The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer
Z. M. A. Mohammed et al.
BRITISH JOURNAL OF CANCER (2012)
Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
Qingfei Wang et al.
CANCER RESEARCH (2012)
Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: Unusually high frequency of down-regulation in breast cancer tissues
Toshihiko Torigoe et al.
PATHOLOGY INTERNATIONAL (2012)
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
Masayuki Inoue et al.
ONCOIMMUNOLOGY (2012)
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study
Ines Vaz-Luis et al.
BREAST CANCER RESEARCH (2012)
Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer
Ludovic Martinet et al.
CANCER RESEARCH (2011)
Vascular characterisation of triple negative breast carcinomas using dynamic MRI
Sonia P. Li et al.
EUROPEAN RADIOLOGY (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial
S. E. Pinder et al.
BRITISH JOURNAL OF CANCER (2010)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
Teemu T. Junttila et al.
CANCER RESEARCH (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF ONCOLOGY PRACTICE (2010)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
Inflammation and prognosis in colorectal cancer
K Klintrup et al.
EUROPEAN JOURNAL OF CANCER (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
R Gennari et al.
CLINICAL CANCER RESEARCH (2004)
Ligands for L-selectin: Homing, inflammation, and beyond
SD Rosen
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
